05:20 AM EST, 11/05/2024 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier.

A single analyst polled by Capital IQ expected $0.02.

Revenue for the quarter ended Sept. 30 was $175.7 million, up from $153.9 million a year earlier.

Four analysts surveyed by Capital IQ expected $157.3 million.

For 2024, the life sciences company raised its revenue guidance to between $630 million to $650 million, from the previous range of $600 million to $625 million. Four analysts polled by Capital IQ expect $642.2 million.

Shares of the company were up more than 6% in recent Tuesday premarket activity.

Price: 37.00, Change: +2.30, Percent Change: +6.63